Molbio Diagnostics is set to open its Rs 940 crore initial public offering (IPO) on Monday. Ahead of the issue opening, the latest grey market premium (GMP) of Molbio Diagnostics stands at Rs 122, indicating a potential listing gain of 15.12% over the upper price band of Rs 807.
Note: Grey market premiums are unofficial and may not accurately reflect the stock's actual listing performance.
Investors considering the Molbio Diagnostics IPO should keep these key details in mind before subscribing.
Molbio Diagnostics IPO GMP Today
Molbio Diagnostics IPO's latest grey market premium (GMP) stood at Rs 122 as of Aug. 10. With the upper price band fixed at Rs 807, the estimated listing price is Rs 929, implying a potential listing gain of 15.12% per share.
Molbio Diagnostics IPO Key Details
Molbio Diagnostics public issue is worth Rs 939.70 crore, comprising a fresh issue of 25 lakh shares aggregating to Rs 200 crore and offer-for-sale (OFS) of 92 lakh shares aggregating to Rs 739.70 crore. Molbio Diagnostics IPO has set issue price band at Rs 768 to Rs 807 per share.
The lot size for an application is 18 shares. This means that the minimum amount of investment required by an individual investor (retail) is Rs 14,526 (18 shares) based on the upper price band. Kotak Mahindra Capital Co. Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
ALSO READ: Dhoot Transmission Raises Rs 918 Crore From 72 Anchor Investors Ahead Of IPO
Molbio Diagnostics IPO Key Dates
- Issue opens: Aug. 10
- Issue closes: Aug. 12
- Allotment finalization: Aug. 13
- Refund initiation: Aug. 14
- Share credit: Aug. 14
- Listing date: Aug. 17
Use of Proceeds
The IPO proceeds will primarily fund research and development infrastructure, a Center of Excellence and connected office space. Some portion will also go towards the purchase of plant, machinery and equipment for Goa and Visakhapatnam units. The remaining proceeds will support general corporate purposes.
Molbio Diagnostics Business
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialisation of rapid diagnostic solutions for infectious and non-communicable diseases.
Molbio Diagnostics Financials
The company reported total income at Rs 1,455.17 crore in FY26, up from Rs 1,027.94 crore in FY25. Profit After Tax (PAT) was at Rs 164.14 crore in FY26, compared with Rs 138.58 crore in FY25. EBITDA stood at Rs 328.24 crore in FY26, up from Rs 256.64 crore in FY25.
ALSO READ: Ardee Industries IPO Closes: Issue Subscribed 133 Times; GMP Signals 28% Listing Premium
Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read red herring prospectus thoroughly before placing bids.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
